Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV Gene Therapy (LYS-SAF302) for MPS IIIA
NCT03612869Phase 3Unknown
- Sponsor
- Lysogene
- Start
- Dec 2018
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 5
01
Overview
A Phase 3 trial of Olenasufligene relduparvovec in mucopolysaccharidosis type III A, sponsored by Lysogene. Status: unknown.
02
Drugs
Olenasufligene relduparvovec
03
Conditions
mucopolysaccharidosis type III A
Beyond the preview
Go deeper on NCT03612869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612869.